Neoadjuvant Hedgehog Pathway Inhibitor (HPI) therapy, utilizing sonidegib and vismodegib, has shown great potential in managing locally advanced basal cell carcinoma (laBCC). While effective, the tolerability of HPI therapy may be limited due to adverse effects (muscle spasms, alopecia). However, studies have shown a lower incidence of side effects with sonidegib, compared to vismodegib. In this report, we present the case of an 86-year-old male with laBCC on the left inner canthus treated successfully with neoadjuvant sonidegib for 25 weeks prior to Mohs micrographic surgery. This case highlights the utility of sonidegib as a potential neoadjuvant treatment modality for patients who are good candidates for surgery but would benefit from tumor reduction to achieve a more favorable outcome, especially in cosmetically sensitive areas. In addition, our patient experienced minimal side effects (muscle cramps at week 18) from sonidegib treatment. J Drugs Dermatol. 2025;24(3):329-331. doi:10.36849/JDD.8329.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.36849/JDD.8329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant Hedgehog Pathway Inhibitor (HPI) therapy, utilizing sonidegib and vismodegib, has shown great potential in managing locally advanced basal cell carcinoma (laBCC). While effective, the tolerability of HPI therapy may be limited due to adverse effects (muscle spasms, alopecia). However, studies have shown a lower incidence of side effects with sonidegib, compared to vismodegib.
View Article and Find Full Text PDFTherapeutic Approaches for Advanced Basal Cell Carcinoma: A Comprehensive Review.
Cancers (Basel)
December 2024
Department of Dermatology and Allergology, Paracelsus Medical University, Muellner Hauptstraße 48, 5020 Salzburg, Austria.
Basal cell carcinoma (BCC) accounts for 80% of skin cancer cases. Although mostly curable by simple excision, the treatment of advanced disease can be challenging, as curative surgery or radiotherapy may not always be feasible. The scope of this review is to summarize current knowledge on molecular mechanisms in BCC pathogenesis, to elaborate on the definition of advanced/difficult-to-treat BCC, and to outline systemic treatment options.
View Article and Find Full Text PDFOral Hedgehog Inhibitor, Vismodegib, for Locally Advanced Periorbital and Orbital Basal Cell Carcinoma: A Report by the American Academy of Ophthalmology.
Ophthalmology
November 2024
Department of Ophthalmology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Article Synopsis
- The review analyzed the effectiveness and safety of oral vismodegib (Erivedge) for treating locally advanced basal cell carcinoma (BCC) in the orbit and periorbital area, finding 16 relevant studies out of 60 identified.
- Results showed high response rates, with some studies reporting up to 100% patient response and significant tumor volume reduction, which helped preserve the eye in most cases, but many patients still required surgery for recurrences.
- Common side effects, experienced by nearly all patients, included muscle cramps, alopecia, and fatigue, leading to therapy discontinuation in some; critical mutations in tumors were also noted, indicating potential resistance to future treatments.
Deceptive pigment changes in neoadjuvant sonidegib therapy for basal cell carcinoma.
Br J Dermatol
August 2024
Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.
Personalized treatment concepts in extraocular cancer.
Adv Ophthalmol Pract Res
March 2024
Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Straße, Cologne, Germany.
Article Synopsis
- The periocular skin is highly susceptible to both benign and malignant tumors, with malignancies in this area being more aggressive and harder to treat compared to other skin regions.
- Recent advancements in immunotherapy have enabled the immune system to effectively target and destroy cancer cells, particularly benefiting the treatment of periocular tumors.
- The choice of treatment for periocular skin cancer should be individualized based on tumor type, size, and genetic factors, and may involve a combination of chemotherapy and immunotherapy options.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!